Incorporating molecular tools into early-stage clinical trials

PLoS Medicine

Volumn 5, Issue 1, 2008, Pages 0034-0038

  Weil, Robert J ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; MONOTHERAPY; NONHUMAN; WORLD HEALTH ORGANIZATION; ANIMAL; BRAIN TUMOR; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENETICS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GLIOBLASTOMA; HUMANS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 38849122572     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050021     Document Type: Article

References (37)

1. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459.
2. Arbiser JL (2007) Why targeted therapy hasn't worked in advanced cancer. J Clin Invest 117: 2762-2765.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037.
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
5. Vogelbaum MA, Peereboom D, Stevens G, Barnett GH, Brewer C (2004) Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme: results of a phase II study [abstract TA-359]. Proceedings of the Ninth Meeting of the Society for Neuro-Oncology; 18-21 November 2004; Toronto, Ontario, Canada.
6. Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, et al. (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8: 67-78.
7. Halatsch ME, Gehrke EE, Vougioukas VI, Botefur IC, A-Borhani F, et al.(2004) Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg 100: 523-533.
8. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-7270.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
10. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, et al (1994) Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56: 72-77.
11. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, et al (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147.
12. Halatsch ME, Gehrke E, Borhani FA, Efferth T, Werner C, et al (2003) EGFR but not PDGFR-beta expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines. Anticancer Res 23: 2315-2320.
13. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, et al. (1990) Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50: 6039-6044.
14. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962-6970.
15. Barker FG 2nd, Simmons ML, Chang SM, Prados MD, Larson DA, et al. (2001) EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51: 410-418.
16. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS (2002) The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62: 4307-4315.
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
18. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, et al. (2005) Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [abstract 77]. 2005 Gastrointestinal Cancers Symposium; 27-29 January 2005; Hollywood, Florida, United States of America. Available: http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 36&abstractID=10376. Accessed 17 December 2007.
19. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024.
20. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880-887.
21. Mellinghoff IK, Cloughesy TF, Mischel PS (2007) PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 13: 378-381.
22. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, et al. (2007) Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6: 1167-1174.
23. Omuro AM, Faivre S, Raymond A (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6: 1909-1919.
24. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, et al. (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66: 7864-7869.
25. McLendon RE, Turner K, Perkinson K, Rich J (2007) Second messenger systems in human gliomas. Arch Pathol Lab Med 131: 1585-1590.
26. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
27. LoPiccolo J, Granville CA, Gills JJ, Dennis PA (2007) Targeting Akt in cancer therapy. Anticancer Drugs 18: 861-874.
28. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD (2006) S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 24: 185-197.
29. Ellis MJ, Crowder R (2007) "PIKing" the winner for phosphatidylinositol 3-kinase inhibitors in ErbB2-positive breast cancer: let's not "PTENed" it's easy! Clin Cancer Res 13: 5661-5662.
30. Huang PH, Cavenee WK, Furnari FB, White FM (2007) Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle 6: 2750-2754.
31. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, et al. (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 104: 12867-12872.
32. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, et al. (2008) Antitumor activity of rapamycin in patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5: e8. doi:10.1371/journal.pmed.0050008
33. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
34. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290.
35. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, et al. (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117: 2766-2777.
36. Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, et al. (2007) Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 117: 1876-1883.
37. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, et al. (2007) Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 7: 131-139.